Antiplatelet agents in stroke prevention

R. Weber; C. Weimar; H.-C. Diener

doi:10.1055/s-0037-1617130

Hämostaseologie, Table of Contents

Hamostaseologie 2009; 29(04): 326-333
DOI: 10.1055/s-0037-1617130

Review

Schattauer GmbH

Antiplatelet agents in stroke prevention

Acute and long-term treatment strategiesThrombozytenfunktionshemmer in der akuten und langfristigen SchlaganfallpräventionAkute und langfristige Behandlungsstrategien

Authors

R. Weber

¹Department of Neurology and Stroke Center, University Duisburg-Essen, Essen, Germany
C. Weimar

¹Department of Neurology and Stroke Center, University Duisburg-Essen, Essen, Germany
H.-C. Diener

¹Department of Neurology and Stroke Center, University Duisburg-Essen, Essen, Germany

Abstract

Summary

In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced. Only aspirin has been shown to be safe and effective in large randomized trials in the first 48 hours after ischemic stroke. Aspirin/dipyridamole and clopidogrel both reduce the risk of a combined cardiovascular outcome in long-term secondary prevention compared to aspirin alone. More potent antiplatelet drugs or combination of aspirin and clopidogrel prevent more ischemic events, but also lead to more bleeding complications. No benefit of oral anticoagulants could be shown in patients with non-cardioembolic stroke. In patients with atrial fibrillation oral anticoagulation is more effective than aspirin in stroke prevention. The choice between oral anticoagulants and aspirin in these patients depends on age and the individual risk factor profile. Patients with symptomatic intracranial stenosis have a higher risk of intracerebral bleeding with oral anticoagulation compared to high dose aspirin. Aspirin is the recommended treatment in stroke patients with a patent foramen ovale.

Zusammenfassung

Aspirin ist in der Schlaganfall-Primärprophylaxe bei Frauen wirksam, während es bei Männern zwar das Herzinfarktrisiko, aber nicht signifikant das Schlaganfallrisiko senkt. Bisher wurde nur für Aspirin ein Nutzen in der Akutbehandlung (erste 48 Stunden) des ischämischen Schlaganfalles nachgewiesen. Sowohl die Kombination Aspirin/Dipyridamol als auch Clopidogrel sind in der Verhinderung kardiovaskulärer Ereignisse wirksamer als eine Aspirin-Monotherapie. Potentere Thrombozytenfunktionshemmer oder die Kombination Aspirin/Clopidogrel können zwar mehr ischämische Ereignisse verhindern, sind aber mit einem deutlich höheren Blutungsrisiko bei Schlaganfallpatienten behaftet. Bei Patienten mit einem nicht kardioembolischen Schlag -anfall sind Thrombozytenfunktionshemmer einer oralen Antikoagulation aufgrund eines geringeren Blutungsrisikos vorzuziehen. Die orale Antikoagulation ist bei nachgewiesenem Vorhofflimmern in der Schlaganfallprävention wirksamer als Thrombozytenfunktionshemmer und sollte anhand des Lebens-alters und dem individuellen Risikoprofil erfolgen. Aspirin ist sowohl bei Schlaganfallpatienten mit intrakraniellen Stenosen als auch bei einem nachgewiesenen offenen Foramen ovale das Mittel der ersten Wahl.

Keywords

Ischaemic stroke - transient ischaemic attack - antiplatelet - primary prevention - secondary prevention - anticoagulation

Schlüsselwörter

Schlüsselwörter Ischämischer Schlaganfall - transiente ischämische Attacke - Thrombozytenfunktions -hemmer - Primärprävention - Sekundärprävention - Antikoagulation

Full Text

References

References
1 Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study.. The Abciximab in Ischemic Stroke Investigators. Stroke 2000; 31: 601-609.
2 Aspirin effects on mortality and morbidity in patients with diabetes mellitus.. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268: 1292-1300.
3 CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349: 1641-1649.
4 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5 Dutch TIA Trial Study Group.. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266.
6 Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005; 36: 880-890.
7 Final report on the aspirin component of the ongoing Physicians’ Health Study.. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129-135.
8 Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Cerebrovasc Dis 2008; 25: 457-507.
9 The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke.. International Stroke Trial Collaborative Group. Lancet 1997; 349: 1569-1581.
10 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) .. CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
11 A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42: 857-865.
12 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342: 1255-1262.
13 Adams Jr HP, Effron MB, Torner J. et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87-99.
14 Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6: 115-124.
15 Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255.
16 Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006; 98: 746-750.
17 Berger JS, Roncaglioni MC, Avanzini F. et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295: 306-313.
18 Bhatt DL, Flather MD, Hacke W. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
19 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
20 Campbell CL, Smyth S, Montalescot G. et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297: 2018-2024.
21 Chimowitz MI, Lynn MJ, Howlett-Smith H. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
22 Connolly S, Pogue J, Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
23 Connolly SJ, Pogue J, Hart RG. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
24 Costa J, Ferro JM, Matias-Guiu J. et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; CD004296.
25 de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
26 Diener H, and Davidai G. Dipyridamole and headache. Future Neurol 2007; 2: 279-283.
27 Diener HC. Stroke prevention: anti-platelet and anti-thrombolytic therapy. Neurol Clin 2000; 18: 343-355.
28 Diener HC, Aichner F, Bode C. et al. Primär- und Sekundärprävention der zerebralen Ischämie. In: Diener HC, Putzki N, Berlit P. et al (eds). Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2008: 261-287.
29 Diener HC, Allenberg JR, Bode C. et al. Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär und Sekundärprophylaxe des Schlaganfalls: Aktualisie-rung 2007. Akt Neurol 2007; 34: 8-12.
30 Diener HC, Bogousslavsky J, Brass LM. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
31 Diener HC, Cunha L, Forbes C. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
32 Diener HC, Darius H, Bertrand-Hardy JM. et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55: 162-163.
33 Farrell B, Godwin J, Richards S. et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
34 Flaker GC, Gruber M, Connolly SJ. et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152: 967-973.
35 Fuster V, Ryden LE, Cannom DS. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006; 114: e257-354.
36 Giles MF, and Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6: 1063-1072.
37 Grau AJ, Weimar C, Buggle F. et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001; 32: 2559-2566.
38 Hacke W, Kaste M, Bluhmki E. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
39 Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59: 17-20.
40 Halkes PH, Gray LJ, Bath PM. et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008; 79: 1218-1223.
41 Halkes PH, van Gijn J, Kappelle LJ. et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
42 Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
43 Hart RG, Benavente O, McBride R. et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
44 Hart RG, Halperin JL, Pearce LA. et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138: 831-838.
45 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
46 Homma S, Sacco RL, Di Tullio MR. et al. Effect of medical treatment in stroke patients with patent for-amen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-2631.
47 Huang Y, Cheng Y, Wu J. et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
48 Iso H, Hennekens CH, Stampfer MJ. et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999; 30: 1764-1771.
49 Kennedy J, Hill MD, Ryckborst KJ. et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969.
50 Lavallee PC, Meseguer E, Abboud H. et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol 2007; 6: 953-960.
51 Leonardi-Bee J, Bath PM, Bousser MG. et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162-168.
52 Lopez AD, Mathers CD, Ezzati M. et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
53 Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-573.
54 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
55 Mas JL, Arquizan C, Lamy C. et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740-1746.
56 Meissner I, Whisnant JP, Khandheria BK. et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 1999; 74: 862-869.
57 Mohr JP, Thompson JL, Lazar RM. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451.
58 Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 1172-1179.
59 Patrono C, Coller B, FitzGerald GA. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
60 Patrono C, Garcia Rodriguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
61 Peto R, Gray R, Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-316.
62 Rothwell PM, Giles MF, Chandratheva A. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432-1442.
63 Sacco RL, Diener HC, Yusuf S. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
64 Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovasc Dis 2008; 26: 93-94.
65 Shinohara Y, Nishimaru K, Sawada T. et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 2008; 39: 1827-1833.
66 Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J 2008; 29: 1086-1092.
67 Topol EJ, Easton D, Harrington RA. et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406.
68 Usman MH, Notaro LA, Nagarakanti R. et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?. Am J Cardiol 2009; 103: 1107-1112.
69 Weimar C, Diener HC, Alberts MJ. et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2009; 40: 350-354.
70 Weimar C, Goertler M, Rother J. et al. Predictive value of the Essen Stroke Risk Score and Ankle Brachial Index in Acute Ischemic Stroke Patients from 85 German Stroke Units. J Neurol Neurosurg Psychiatry 2008; 79: 1339-1343.
71 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
72 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.